Previous 10 | Next 10 |
Gilead Sciences ( GILD ) announced two key news items recently. It started off with positive proof of concept NASH results with a double combination treatment, which was presented at the International Liver Congress 2019. Then a few days later, it announced a partnership with Novo Nordisk ( NV...
Quick Take Axcella Health ( AXLA ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for the treatment of metabolism-related conditions of the liver, muscles, and blood. AXLA is not curre...
Madrigal Pharmaceuticals ( MDGL ) is a US biotech company that currently has only one drug, MGL-3196, under clinical investigation stage. Being Madrigal’s key asset, MGL-3196 has proven its strong potential in Non-Alcoholic Steatohepatitis ((NASH)) and is currently advancing to Phase ...
Selling the (lack of) news Investors often "sell the news" because it's old news and thus is, so the sellers think, more-than-fully priced in. When the selling reaches a 30% haircut, as it did at the end of the week with Intercept Pharmaceuticals ( ICPT ), it tends to force anyone interest...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with this Read more ...
Novartis (NVS) is looking to push a new anti-inflammatory drug, after acquiring IFM Tre, which is a subsidiary of Therapeutics LLC . It's good news because it gives the big pharma a leg up on treating inflammatory disorders. The newly acquired drugs will not only be used for inflammation, t...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
ATA (NASDAQ: ATAI ) -21% . More news on: ATA Inc., Marathon Patent Group, Inc., Bed Bath & Beyond Inc., Stocks on the move, Read more ...
Intercept Pharmaceuticals (NASDAQ: ICPT ) announces more data from the Phase 3 REGENERATE clinical trial evaluating obeticholic acid (OCA) in NASH patients with liver fibrosis. The results are being presented at The International Liver Congress in Vienna. More news on: Intercept P...
OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters REGENERATE data to be presented during the Opening Ceremony of EASL NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...